$800 Million is the total value of BROADWOOD CAPITAL INC's 7 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MNST | MONSTER BEVERAGE CORP NEW | $298,680,000 | +16.9% | 4,679,308 | 0.0% | 37.34% | +19.4% | |
| IWM | ISHARES TRrussell 2000 etf | $65,310,000 | +1.6% | 420,000 | 0.0% | 8.16% | +3.7% | |
| AXON | AXON ENTERPRISE INC | $48,804,000 | +18.0% | 760,062 | 0.0% | 6.10% | +20.5% | |
| OCX | ONCOCYTE CORPORATION | $20,165,000 | -37.0% | 8,098,267 | 0.0% | 2.52% | -35.6% | |
| AGE | AGEX THERAPEUTICS INC | $11,000,000 | -9.4% | 2,997,156 | 0.0% | 1.38% | -7.5% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STAAR SURGICAL CO | 42 | Q3 2023 | 59.1% |
| MONSTER BEVERAGE CORP NEW | 34 | Q3 2023 | 49.7% |
| ISHARES TR | 33 | Q3 2023 | 14.8% |
| ONCOCYTE CORPORATION | 31 | Q2 2023 | 4.6% |
| BIOTIME INC | 25 | Q2 2019 | 17.8% |
| AXON ENTERPRISE INC | 24 | Q3 2023 | 13.4% |
| AGEX THERAPEUTICS INC | 20 | Q3 2023 | 1.5% |
| LINEAGE CELL THERAPEUTICS INC | 17 | Q3 2023 | 5.1% |
| ASTERIAS BIOTHERAPEUTICS INC | 16 | Q4 2018 | 2.9% |
| CYNOSURE INC | 15 | Q4 2016 | 10.4% |
View BROADWOOD CAPITAL INC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 4 | 2024-04-15 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 4 | 2024-01-10 |
| 4 | 2024-01-05 |
| 4 | 2023-11-30 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-11-14 |
View BROADWOOD CAPITAL INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.